Form 4: Hims & Hers Health CEO Andrew Dudum Executes Stock Options and Sells Shares Under 10b5-1 Plan

Hims & Hers Health CEO Andrew Dudum exercised stock options and sold shares of Class A Common Stock on May 16, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 16, 2025, Andrew Dudum, CEO of Hims & Hers Health, Inc., engaged in transactions involving the company's Class A Common Stock.
• Dudum exercised stock options to acquire shares at a price of $2.43.
• He then sold a portion of these shares at varying prices ranging from approximately $57.42 to $59.525.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 28, 2024.
• The transactions involved both direct and indirect holdings, including shares held in various trusts.
• Following these transactions, Dudum continues to hold a significant number of shares both directly and indirectly through various trusts.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are part of a pre-planned trading strategy, mitigating potential negative interpretations. However, any insider selling can create some uncertainty.

Positives

• The transactions were pre-planned under a Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
• Dudum continues to hold a substantial number of shares, indicating ongoing alignment with the company's success.

Negatives

• The sale of shares by the CEO could be perceived negatively by some investors, potentially signaling a lack of confidence, although the 10b5-1 plan mitigates this concern.

Risks

• While the Rule 10b5-1 plan provides a framework, significant sales by insiders can still create short-term market volatility.
• Investor sentiment could be affected if similar sales continue in the future.

Future Outlook

The document does not contain specific forward-looking statements, but the ongoing execution of the Rule 10b5-1 plan suggests continued transactions may occur.

Industry Context

Executive stock transactions are common in publicly traded companies, and the use of Rule 10b5-1 plans is a standard practice to avoid insider trading concerns. The health and wellness industry has seen increased investor interest, and executive actions are closely monitored.

Comparison to Industry Standards

• Many CEOs in publicly traded companies use 10b5-1 plans to manage their stock sales, including those at companies like Teladoc Health and GoodRx.
• The size and frequency of these transactions are typical for executives with significant equity holdings.
• The use of trusts for holding shares is a common estate planning strategy among high-net-worth individuals.

Stakeholder Impact

• Shareholders may react to the stock sales, although the pre-planned nature of the transactions should minimize negative impact.
• Employees may be indirectly affected by any stock price fluctuations.

Key Dates

Keywords

Hims & Hers Health, Andrew Dudum, stock options, Rule 10b5-1, insider trading, Class A Common Stock, stock sale, SEC Form 4